Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis

NCT01682512 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

294

Enrollment

INDUSTRY

Sponsor class

Stopped substance discontinued

Conditions

Arthritis, Rheumatoid

Interventions

DRUG: BI 695500
DRUG: BI 695500
DRUG: Rituxan®
DRUG: Rituxan®
DRUG: MabThera®

Sponsor

Boehringer Ingelheim